Why is the Cochlear share price slipping on Wednesday?

What's going on with Cochlear shares?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Cochlear shares dip 1.5% to $203.84 during morning trade
  • The company's shares are trading ex-dividend today
  • Eligible shareholders will receive a dividend payment of $1.45 per share on 17 October

The Cochlear Limited (ASX: COH) share price is heading south on Wednesday morning.

This comes amid the S&P/ASX 200 Index (ASX: XJO) falling wayside today after global markets dipped on the expectation that the United States Federal Reserve will lift interest rates by 75 basis points.

At the time of writing, the hearing solution company's shares are down 1.5% to $203.84.

An older woman tries to listen by cupping her ear.

Image source: Getty Images

Why are Cochlear shares falling on Wednesday?

Investors are offloading the Cochlear share price as it trades ex-dividend today.

This means if you purchased the company's shares yesterday or before, you will be eligible for the latest dividend.

However, when a company's shares trade ex-dividend, the share price tends to fall in proportion to the dividend paid out. This can also vary on how the market is tracking for the day, as well as investor sentiment.

For those eligible for Cochlear's final dividend, shareholders will receive a payment of $1.45 per share on 17 October.

The dividend is 40% franked.

Are Cochlear shares a buy now?

Following the company's financial scorecard, a number of brokers weighed in on the Cochlear share price.

As reported by ANZ Share Investing, analysts at Morgan Stanley raised its price target by 4.1% to $202 for Cochlear shares.

In addition, the team at Wilsons raised its target by 4% to $245 apiece. Based on the current share price, this implies an upside of roughly 20%.

On the other hand, Macquarie cut its rating to underperform from neutral and slashed its price target by 1.5% to $194.

This indicates a downside of 5% from where Cochlear shares trade today.

Cochlear share price summary

The Cochlear share price has dropped 13.8% over the past 12 months.

In comparison, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down around14% for the same period.

Based on today's price, Cochlear commands a market capitalisation of roughly $13.61 billion, and has a dividend yield of 1.4%.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »